The mTOR Inhibitor Rapamycin Mitigates Perforant Pathway Neurodegeneration and Synapse Loss in a Mouse Model of Early-Stage Alzheimer-Type Tauopathy

Topic: Brain proteins, microglia and lab models

The perforant pathway projection from layer II of the entorhinal cortex to the hippocampal dentate gyrus is especially important for long-term memory formation, and is preferentially vulnerable to developing a degenerative tauopathy early in Alzheimer's disease (AD) that may spread over time trans-synaptically. Despite the importance of the perforant pathway to the clinical onset and progression of AD, a therapeutic has not been identified yet that protects it from tau-mediated toxicity. Here, we used an adeno-associated viral vector-based mouse model of early-stage AD-type tauopathy to investigate effects of the mTOR inhibitor and autophagy stimulator rapamycin on the tau-driven loss of perforant pathway neurons and synapses. Focal expression of human tau carrying a P301L mutation but not eGFP as a control in layer II of the lateral entorhinal cortex triggered rapid degeneration of these neurons, loss of lateral perforant pathway synapses in the dentate gyrus outer molecular layer, and activation of neuroinflammatory microglia and astroglia in the two locations. Chronic systemic rapamycin treatment partially inhibited phosphorylation of a mechanistic target of rapamycin substrate in brain and stimulated LC3 cleavage, a marker of autophagic flux. Compared with vehicle-treated controls, rapamycin protected against the tau-induced neuronal loss, synaptotoxicity, reactive microgliosis and astrogliosis, and activation of innate neuroimmunity. It did not alter human tau mRNA or total protein levels. Finally, rapamycin inhibited trans-synaptic transfer of human tau expression to the dentate granule neuron targets for the perforant pathway, likely by preventing the synaptic spread of the AAV vector in response to pathway degeneration. These results identify systemic rapamycin as a treatment that protects the entorhinal cortex and perforant pathway projection from tau-mediated neurodegeneration, axonal and synapse loss, and neuroinflammatory reactive gliosis. The findings support the potential for slowing the progression of AD by abrogating tau-mediated neurotoxicity at its earliest neuropathological stages.

Key findings

• Compared with vehicle-treated controls, rapamycin protected against the tau-induced neuronal loss, synaptotoxicity, reactive microgliosis and astrogliosis, and activation of innate neuroimmunity.
• These results identify systemic rapamycin as a treatment that protects the entorhinal cortex and perforant pathway projection from tau-mediated neurodegeneration, axonal and synapse loss, and neuroinflammatory reactive gliosis.

Study details

• Evidence strengthLow

Read the original

• DOI: 10.1371/journal.pone.0142340
• PubMed: 26540269
• Original source →

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

@article{siman2015-26540269,
  author  = {Siman, R. and Cocca, R. and Dong, Y.},
  title   = {{The mTOR Inhibitor Rapamycin Mitigates Perforant Pathway Neurodegeneration and Synapse Loss in a Mouse Model of Early-Stage Alzheimer-Type Tauopathy}},
  journal = {PloS one},
  year    = {2015},
  doi     = {10.1371/journal.pone.0142340},
  pmid    = {26540269},
  url     = {https://doi.org/10.1371/journal.pone.0142340}
}

Related studies in Disease mechanisms

• Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease PloS one · 2010-04-01 · usefulness score 40/100
• MK-8719, a Novel and Selective O-GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy The Journal of pharmacology and experimental therapeutics · 2020-06-03 · usefulness score 38/100
• Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway The Journal of neuroscience : the official journal of the Society for Neuroscience · 2007-03-01 · usefulness score 36/100
• Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model Neuron · 2007-02-01 · usefulness score 58/100
• Gut Microbiome–Sphingolipid Metabolism–Brain Axis Interactions: Neuroprotective Effects of Amitriptyline as Functional Inhibitor of Acid Sphingomyelinase in a Mouse Model of Tauopathy Journal of Neuroimmune Pharmacology · 2026-01-03 · usefulness score 37/100
• The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration Cellular signalling · 2014-08-28 · usefulness score 36/100

Similar studies

• Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome 2018 · Down syndrome and Alzheimer's
• Rapamycin alleviates toxicity of different aggregate-prone proteins 2006 · Disease mechanisms
• mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies 2013 · Risk factors
• Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism 2011 · Risk genes beyond APOE
• Restoration of aberrant mTOR signaling by intranasal rapamycin reduces oxidative damage: Focus on HNE-modified proteins in a mouse model of down syndrome 2019 · Down syndrome and Alzheimer's
• Multimodal Transformer Modeling of Rapamycin Treatment in Alzheimer's Disease via Random Forest Feature Filtering 2026 · How common it is

More on Disease mechanisms

• A review that covers this ground Mitochondria take center stage in aging and neurodegeneration Annals of neurology · 2005-10-01 · usefulness score 40/100
• Newest in this subject Aβ42 oligomers disrupt calcium homeostasis via Piezo1 and induce neurotoxicity in differentiated SH-SY5Y cells Research Square · 2026-10-29 · Preprint — not yet peer-reviewed · usefulness score 16/100
• Newest in this subject Neuronal Hyperactivity Induces Tau Phosphorylation Selectively in Excitatory Pyramidal Neurons Which Contributes to GluA2 Regulation bioRxiv · 2026-10-28 · Preprint — not yet peer-reviewed · usefulness score 16/100

See all studies in Disease mechanisms →